Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.
Diabetes Obes MetabJun 25, 2026 (epub)
Alexander Kokkinos, Tina Thethi, Clare J Lee et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials evaluated the efficacy and tolerability of tirzepatide in 2384 participants with obesity or overweight. It found that early responders (≥5% weight reduction by Week 8) experienced significantly greater weight loss and improvements in cardiometabolic risk parameters compared to non-responders, with similar gastrointestinal tolerability profiles.
Key findings
- Early responders achieved greater weight reduction and improvements in CRPs compared to non-responders.
- Participants in the early responder group were more likely to be female and White.
- Both groups experienced clinically meaningful weight reduction and improvements in HbA1c by Week 72.
- The pattern and severity of gastrointestinal events were similar between early and non-responders.
Why it matters
Understanding early weight response to tirzepatide can help clinicians tailor obesity treatment strategies, potentially enhancing patient outcomes in weight management and cardiometabolic health.